The MASH-obesity crossover: mazdutide, pemvidutide, survodutide.
Why metabolic therapy is spilling into liver disease headlines, and how to avoid mixing up weight-loss, liver-fat, and MASH endpoints.
The obesity pipeline increasingly overlaps with cardiometabolic and liver-disease research. Mazdutide, pemvidutide, and survodutide are not interchangeable, but they share a pattern: incretin or glucagon-adjacent mechanisms being tested beyond scale weight alone.
Why endpoints matter
Weight change, liver fat, MASH resolution, fibrosis improvement, glycemic markers, and cardiovascular outcomes are different endpoints. A positive signal in one does not automatically prove broad consumer usefulness in another.
Our coverage rule
We will label these as adjacent pipeline topics, not beauty or wellness shortcuts, and we will keep indication, population, and endpoint language attached to the evidence.
Medical note
This review is for education only and is not medical advice. Treatment decisions should be made with a licensed clinician who knows your history, medications, labs, and goals.